Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio [CORRESPONDENCE]

Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: CORRESPONDENCE Source Type: research